[HTML][HTML] Safety and Immunogenicity of a 4-Component Toxoid-Based Staphylococcus aureus Vaccine in Rhesus Macaques

A Venkatasubramaniam, G Liao, E Cho… - Frontiers in …, 2021 - frontiersin.org
Staphylococcus aureus is a leading cause of significant morbidity and mortality and an
enormous economic burden to public health worldwide. Infections caused by methicillin …

[HTML][HTML] Dry and liquid formulations of IBT-V02, a novel multi-component toxoid vaccine, are effective against Staphylococcus aureus isolates from low-to-middle …

Y Wang, I Mukherjee, A Venkatasubramaniam… - Frontiers in …, 2024 - frontiersin.org
Staphylococcus aureus is the leading cause of skin and soft tissue infections (SSTIs) in the
US as well as more serious invasive diseases, including bacteremia, sepsis, endocarditis …

[HTML][HTML] IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by Staphylococcus aureus

H Karauzum, A Venkatasubramaniam… - Frontiers in …, 2021 - frontiersin.org
Staphylococcus aureus causes a wide range of diseases from skin infections to life
threatening invasive diseases such as bacteremia, endocarditis, pneumonia, surgical site …

[HTML][HTML] Hyperimmune targeting staphylococcal toxins effectively protect against USA 300 MRSA infection in mouse bacteremia and pneumonia models

X Han, R Ortines, I Mukherjee, T Kanipakala… - Frontiers in …, 2022 - frontiersin.org
Staphylococcus aureus has been acquiring multiple drug resistance and has evolved into
superbugs such as Methicillin/Vancomycin-resistant S. aureus (MRSA/VRSA) and …

[PDF][PDF] Recent developments for Staphylococcus aureus vaccines: clinical and basic science challenges

RA Proctor - Eur Cell Mater, 2015 - ecmjournal.org
Bacterial vaccines have made dramatic impacts upon morbidity and mortality caused by a
number of common pathogens, but a vaccine to prevent Staphylococcus aureus infections …

Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial

J Levy, L Licini, E Haelterman, P Moris… - Human vaccines & …, 2015 - Taylor & Francis
We assessed the safety, reactogenicity and immunogenicity of a staphylococcal vaccine
combining capsular polysaccharides types 5 and 8 (CPS5/8), conjugated to tetanus toxoid …

[HTML][HTML] Toxin expression during Staphylococcus aureus infection imprints host immunity to inhibit vaccine efficacy

O Teymournejad, Z Li, P Beesetty, C Yang… - npj Vaccines, 2023 - nature.com
Staphylococcus aureus infections are a major public health issue, and a vaccine is urgently
needed. Despite a considerable promise in preclinical models, all vaccines tested thus far …

Evaluation of recombinant SEA-TSST fusion toxoid for protection against superantigen induced toxicity in mouse model

PN Reddy, S Paul, MH Sripathy, HV Batra - Toxicon, 2015 - Elsevier
Abstract Treatment of Staphylococcus aureus infections has become complicated owing to
growing antibiotic resistance mechanisms and due to the multitude of virulence factors …

Development of combination vaccine conferring optimal protection against six pore-forming toxins of Staphylococcus aureus

QF Zhang, TT Jiang, X Mao, JD Kim, DH Ahn… - Infection and …, 2021 - Am Soc Microbiol
In the Gram-positive pathogen Staphylococcus aureus, pore-forming toxins (PFTs), such as
leukocidins and hemolysins, play prominent roles in staphylococcal pathogenesis by killing …

Immunity to Staphylococcus aureus secreted proteins protects rabbits from serious illnesses

AR Spaulding, YC Lin, JA Merriman, AJ Brosnahan… - Vaccine, 2012 - Elsevier
Staphylococcus aureus causes significant illnesses throughout the world, including toxic
shock syndrome (TSS), pneumonia, and infective endocarditis. Major contributors to S …